Breaking News Instant updates and real-time market news.

ALIOF

Actelion

, JNJ

Johnson & Johnson

$134.35

1.31 (0.98%)

17:08
06/18/17
06/18
17:08
06/18/17
17:08

Actelion granted Orphan designation for macitentan

The FDA granted Actelion (ALIOF) Orphan designation for its macitentan product in the treatment of chronic thromboembolic pulmonary hypertension. The designation was granted June 15, according to an online notice from the agency. Actelion has been acquired by Johnson & Johnson (JNJ). Reference Link

ALIOF

Actelion

JNJ

Johnson & Johnson

$134.35

1.31 (0.98%)

ALIOF Actelion

01/26/17
01/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cognex (CGNX) initiated with a Neutral at JPMorgan. 2. Realogy (RLGY) initiated with a Hold at Deutsche Bank. 3. EQT Midstream Partners (EQM) ande EQT GP (EQGP) were initiated with a Buy at Janney Capital. 4. Williams (WMB) was assumed with an Outperform at Credit Suisse, while Williams Partners (WPZ) was assumed with a Neutral. 5. Actelion (ALIOF) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/17
01/31/17
NO CHANGE

Deutsche sees label warnings as worst case for Actelion drug
After France's National Agency for the Safety of Medicines and Health Products, in a letter dated January 24, asked doctors to stop treating new patients with Actelion's (ALIOF) Uptravi as it investigates patient deaths, Deutsche Bank said it believes a label warnings for the pulmonary arterial hypertension drug is likely the worst case scenario. The firm thinks Johnson & Johnson (JNJ) likely knew of the letter before reaching an agreement to acquire Actelion. Shares of Actelion are down 4% to $65.40 in morning trading.
03/08/17
JPMS
03/08/17
UPGRADE
JPMS
Overweight
Actelion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded Actelion (ALIOF) to Overweight citing a "high confidence" that the Johnson & Johnson (JNJ) buyout will complete. The analyst sees 7% potential return by mid-2017.
04/19/17
UBSW
04/19/17
NO CHANGE
Target $136
UBSW
Buy
Johnson & Johnson weakness a buying opportunity, says UBS
UBS analyst Matt Miksic believes Johnson & Johnson (JNJ) delivered a solid bottom line beat on in-line sales but prior period adjustments impacted Pharma growth, making the as-reported results look less robust. He raised his estimates to include the Actelion (ALIOF), deal which is expected to close in Q2. Miksic views the initial pullback in the stock as creating a particularly attractive entry point for investors. Miksic reiterated his Buy rating and $136 price target on Johnson & Johnson shares.
JNJ Johnson & Johnson
$134.35

1.31 (0.98%)

06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.

TODAY'S FREE FLY STORIES

SAN

Banco Santander

$6.85

0.19 (2.85%)

17:06
06/28/17
06/28
17:06
06/28/17
17:06
Hot Stocks
Santander USA outlines capital plans for Q3 »

Santander Holdings USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$13.32

0.18 (1.37%)

17:05
06/28/17
06/28
17:05
06/28/17
17:05
Syndicate
Breaking Syndicate news story on Bellicum Pharmaceuticals »

Bellicum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

KND

Kindred Healthcare

$11.50

0.25 (2.22%)

17:04
06/28/17
06/28
17:04
06/28/17
17:04
Hot Stocks
Kindred Healthcare to partner on new Montana rehabilitation hospital »

Kindred Healthcare,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$37.02

0.46 (1.26%)

17:02
06/28/17
06/28
17:02
06/28/17
17:02
Hot Stocks
Logitech nominates to new directors, proposes 10% dividend increase »

Logitech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

BLCM

Bellicum Pharmaceuticals

$13.32

0.18 (1.37%)

17:00
06/28/17
06/28
17:00
06/28/17
17:00
Syndicate
Breaking Syndicate news story on Bellicum Pharmaceuticals »

Bellicum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XLF

Financial Select Sector

$24.52

0.38 (1.57%)

17:00
06/28/17
06/28
17:00
06/28/17
17:00
Technical Analysis
Technical View: Financial Select Sector rises in extended trading »

The Financial Select…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$65.18

0.95 (1.48%)

16:58
06/28/17
06/28
16:58
06/28/17
16:58
Technical Analysis
Technical View: Citi rises after hours »

In the extended session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 14

    Jul

  • 20

    Jul

  • 25

    Jul

BAC

Bank of America

$23.88

0.61 (2.62%)

16:54
06/28/17
06/28
16:54
06/28/17
16:54
Hot Stocks
Bank of America to boost quarterly dividend 60%, authorizes $12B share buyback »

Bank of America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNSL

Consolidated Communications

$21.27

0.53 (2.56%)

, FRP

FairPoint

$15.50

0.5 (3.33%)

16:54
06/28/17
06/28
16:54
06/28/17
16:54
Hot Stocks
Consolidated Communications-FairPoint merger secures regulatory approvals »

Consolidated…

CNSL

Consolidated Communications

$21.27

0.53 (2.56%)

FRP

FairPoint

$15.50

0.5 (3.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.24

2.66 (1.77%)

16:54
06/28/17
06/28
16:54
06/28/17
16:54
Periodicals
Facebook creating ad targeting for families, Axios reports »

Facebook is creating new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NTRS

Northern Trust

$96.66

1.24 (1.30%)

16:52
06/28/17
06/28
16:52
06/28/17
16:52
Hot Stocks
Northern Trust to increase dividend to 42c per share, buy back $750M in stock »

Northern Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

SBOT

Stellar Biotechnologies

$1.23

-0.05 (-3.91%)

16:51
06/28/17
06/28
16:51
06/28/17
16:51
Hot Stocks
Breaking Hot Stocks news story on Stellar Biotechnologies »

Frank R. Oakes reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$71.94

0.14 (0.19%)

16:51
06/28/17
06/28
16:51
06/28/17
16:51
Hot Stocks
Comerica plans to increase dividend 15%, buy back up to $605M of common stock »

Comerica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$89.82

1.77 (2.01%)

16:50
06/28/17
06/28
16:50
06/28/17
16:50
Hot Stocks
JPMorgan to up quarterly dividend to 56c/share, authorizes $19.4B share buyback »

JPMorgan Chase & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

BBVA

Banco Bilbao

$8.54

0.16 (1.91%)

16:50
06/28/17
06/28
16:50
06/28/17
16:50
Hot Stocks
BBVA Compass receives no objection to its 2017 capital plan »

BBVA Compass Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ZION

Zions Bancorp

$42.97

0.43 (1.01%)

16:49
06/28/17
06/28
16:49
06/28/17
16:49
Hot Stocks
Zions to boost common dividend to 24c per share by 2Q18 »

The Board of Governors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$123.40

2.28 (1.88%)

16:48
06/28/17
06/28
16:48
06/28/17
16:48
Hot Stocks
PNC says proposed capital plans include 36% dividend hike, $2.7B in buybacks »

The PNC Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

MBUU

Malibu Boats

$25.75

0.28 (1.10%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
Malibu Boats to acquire Cobalt Boats for $130M »

Malibu Boats announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$48.61

0.27 (0.56%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
CIT Group receives no objection to its 2017 capital plan »

CIT Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$61.88

0.81 (1.33%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
Discover to boost quarterly dividend to 35c per share, authorizes $2.23B buyback »

Discover Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AMZN

Amazon.com

$990.33

13.55 (1.39%)

, WMT

Wal-Mart

$76.51

0.5 (0.66%)

16:46
06/28/17
06/28
16:46
06/28/17
16:46
Periodicals
Amazon holds first ever 'meet and greet' for sellers, Bloomberg says »

Amazon (AMZN) is holding…

AMZN

Amazon.com

$990.33

13.55 (1.39%)

WMT

Wal-Mart

$76.51

0.5 (0.66%)

EBAY

eBay

$35.31

0.4 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

STI

SunTrust

$56.09

0.88 (1.59%)

16:46
06/28/17
06/28
16:46
06/28/17
16:46
Hot Stocks
SunTrust boosts quarterly dividend 54%, authorizes $1.32B share buyback »

SunTrust Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

KEY

KeyCorp

$18.38

0.18 (0.99%)

16:44
06/28/17
06/28
16:44
06/28/17
16:44
Hot Stocks
KeyCorp to boost quarterly dividend to 10.5c per share, to repurchase $800M »

KeyCorp announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$50.60

0.92 (1.85%)

16:43
06/28/17
06/28
16:43
06/28/17
16:43
Hot Stocks
BNY Mellon to raise dividend 24%, repurchase up to $3.1B of common stock »

BNY Mellon announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

CFG

Citizens Financial

$35.34

0.5 (1.44%)

16:42
06/28/17
06/28
16:42
06/28/17
16:42
Hot Stocks
Citizens Financial plans 18c per share quarterly dividends, $850M share buyback »

Citizens Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.